PL4222147T3 - Pochodne tiadiazolonu i ich zastosowanie jako agonistów ampk w leczeniu cukrzycy i powiązanych z nią zaburzeń - Google Patents

Pochodne tiadiazolonu i ich zastosowanie jako agonistów ampk w leczeniu cukrzycy i powiązanych z nią zaburzeń

Info

Publication number
PL4222147T3
PL4222147T3 PL21816508.2T PL21816508T PL4222147T3 PL 4222147 T3 PL4222147 T3 PL 4222147T3 PL 21816508 T PL21816508 T PL 21816508T PL 4222147 T3 PL4222147 T3 PL 4222147T3
Authority
PL
Poland
Prior art keywords
thiadiazolone
diabetes
derivatives
treatment
related disorders
Prior art date
Application number
PL21816508.2T
Other languages
English (en)
Polish (pl)
Inventor
Thomas Edlund
Jacob Westman
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of PL4222147T3 publication Critical patent/PL4222147T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL21816508.2T 2020-10-01 2021-09-30 Pochodne tiadiazolonu i ich zastosowanie jako agonistów ampk w leczeniu cukrzycy i powiązanych z nią zaburzeń PL4222147T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2015585.9A GB202015585D0 (en) 2020-10-01 2020-10-01 New compounds
PCT/GB2021/052535 WO2022069894A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Publications (1)

Publication Number Publication Date
PL4222147T3 true PL4222147T3 (pl) 2025-06-09

Family

ID=73223766

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21816508.2T PL4222147T3 (pl) 2020-10-01 2021-09-30 Pochodne tiadiazolonu i ich zastosowanie jako agonistów ampk w leczeniu cukrzycy i powiązanych z nią zaburzeń

Country Status (13)

Country Link
US (1) US12643918B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222147B1 (cg-RX-API-DMAC7.html)
JP (1) JP7793614B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079163A (cg-RX-API-DMAC7.html)
CN (1) CN116368141B (cg-RX-API-DMAC7.html)
AU (1) AU2021352146A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193947A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018732T3 (cg-RX-API-DMAC7.html)
GB (1) GB202015585D0 (cg-RX-API-DMAC7.html)
HU (1) HUE071685T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023003825A (cg-RX-API-DMAC7.html)
PL (1) PL4222147T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022069894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JPWO2024075784A1 (cg-RX-API-DMAC7.html) * 2022-10-05 2024-04-11

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010270030B2 (en) 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
GB201915094D0 (en) 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Also Published As

Publication number Publication date
ES3018732T3 (en) 2025-05-19
GB202015585D0 (en) 2020-11-18
MX2023003825A (es) 2023-06-06
EP4222147B1 (en) 2025-03-19
CN116368141A (zh) 2023-06-30
HUE071685T2 (hu) 2025-09-28
JP2023543924A (ja) 2023-10-18
CA3193947A1 (en) 2022-04-07
KR20230079163A (ko) 2023-06-05
AU2021352146A1 (en) 2023-06-01
US12643918B2 (en) 2026-06-02
WO2022069894A1 (en) 2022-04-07
JP7793614B2 (ja) 2026-01-05
EP4222147A1 (en) 2023-08-09
EP4222147C0 (en) 2025-03-19
US20230382930A1 (en) 2023-11-30
CN116368141B (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
HUE071685T2 (hu) Tiadiazolon-származékok és alkalmazásuk AMPK agonistákként diabétesz és kapcsolódó rendellenességek kezelésében
AU2021352146A9 (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
ZA201009003B (en) Use of angiogenin or angiogenin agonists for treating diseases and disorders
PA8780101A1 (es) Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
IL286180A (en) Heteroaromatic and aromatic tricyclic derivatives for the treatment of diseases associated with iron-dependent cell death
IL287280A (en) Compounds and methods for the treatment of ocular disorders
SG11202107497XA (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
PL3956310T3 (pl) <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div>
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
SG11202107659SA (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
UY30032A1 (es) Compuestos de cinolina, composiciones farmacéuticas que los contienen y procesos para la preparación y uso de los mismos
ECSP22035103A (es) Inhibidores de los receptores a2c adrenérgicos
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL269400A (en) Medicines and preparations for the treatment of eye disorders
PL3846788T3 (pl) Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
EP3854401A4 (en) CDC7 INHIBITING PURE INDIVIDUALS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL CONDITIONS
IL290035A (en) History of pyridine as tmem16a modulators for use in the treatment of respiratory conditions
LT3906927T (lt) Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
IL327100A (en) Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
HK40059430A (en) Composition and use for the treatment of parkinson's disease and related disorders